Direct-acting antivirals for chronic hepatitis C treatment: The experience of two tertiary university centers in Brazil

doi:10.4254/wjh.v14.i1.195

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 14, Issue 1

This Article

Academic Content and Language Evaluation of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (3903)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Tables (1-6) series.

Item

Count

PDF

263

WORD

114

HTML

1962

Tables (1-6)

269

Sum=2608

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

446

Download

849

Sum=1295

Jan 27, 2022 (publication date) through Nov 26, 2024

Times Cited of This Article

Times Cited (1)

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Cohort Study

World J Hepatol. Jan 27, 2022; 14(1): 195-208
Published online Jan 27, 2022. doi: 10.4254/wjh.v14.i1.195

Table 3 Sustained virologic response rates according to therapeutic regimens, hepatitis C virus genotypes and cirrhosis

SVR	ITT (n = 532), % (n)	m-ITT (n = 509), % (n)
Global	92.6% (493/532)	96.8% (493/509)
Genotype
1	93.7% (392/418)	97.7% (392/401)
2	100% (4/4)	100% (4/4)
3	87.8% (94/107)	93.0% (94/101)
4	100% (2/2)	100% (2/2)
5	100% (1/1)	100% (1/1)
Treatment regimen
3D ± RBV	100% (15/15)	100% (15/15)
SOF + DCV	86.1% (81/94)	95.2% (81/85)
SOF + DCV + RBV	94.2% (247/262)	97.2% (247/254)
SOF + RBV	100% (3/3)	100% (3/3)
SOF + SMV	92% (104/113)	96.3% (104/108)
SOF + SMV + RBV	95.3% (41/43)	97.6% (41/42)
SOF + LED ± RBV	100% (2/2)	100% (2/2)
Presence of cirrhosis
No	94.6% (214/226)	98.6% (214/217)
Yes	91.1% (279/306)	95.5% (279/292)

3D: Veruprevir/ritonavir, ombitasvir and dasabuvir; DCV: Daclatasvir; HCV: Hepatitis C virus; ITT: Intention-to-treat; m-ITT: Modified intention-to-treat; LED: Ledipasvir; RBV: Ribavirin; SMV: Simeprevir; SOF: Sofosbuvir; SVR: Sustained virologic response.

Citation: Lourenço MS, Zitelli PMY, Cunha-Silva M, Oliveira AIN, Oliveira CP, Sevá-Pereira T, Carrilho FJ, Pessoa MG, Mazo DF. Direct-acting antivirals for chronic hepatitis C treatment: The experience of two tertiary university centers in Brazil. World J Hepatol 2022; 14(1): 195-208
URL: https://www.wjgnet.com/1948-5182/full/v14/i1/195.htm
DOI: https://dx.doi.org/10.4254/wjh.v14.i1.195